You are here: Urology Textbook > Drugs in Urology > Supportive therapy of neutropenia

Prophylaxis and Treatment of Chemotherapy-Induced Neutropenia

Definitions of Neutropenia

Neutropenia is defined as an absolute neutrophil count (ANC) <500/μl, or an ANC <1000/μl with an expected decline to <500/μl within the next 48 hours (Naurois et al., 2010).

Asymptomatic Neutropenia

The definition of neutropenia above applies, and the patient does not have fever (body temperature <38 °C). The risk of infection increases, particularly with profound and/or prolonged neutropenia.

Febrile Neutropenia

The definition of neutropenia above applies, and the patient has fever (oral temperature ≥38.0 °C sustained for at least 1 hour, or a single measurement ≥38.3 °C). Mortality varies depending on comorbidities, the causative pathogen and resistance patterns, and the individual risk profile (see the MASCC risk score table).

• Low-risk patient: MASCC score ≥21.
• High-risk patient: MASCC score <21.

CTCAE Grading of Neutropenia (Version 6.0)

• Grade 0: Neutrophil count (ANC) within the reference range
• Grade 1: ANC 1000–1500/μl
• Grade 2: ANC 500–1000/μl
• Grade 3: ANC 100–500/μl
• Grade 4: ANC <100/μl
• Grade 5: Death related to complications of neutropenia

Diagnosis

Recommended diagnostic evaluation for febrile neutropenia (initial workup):

• Complete blood count with differential
• aPTT, INR (or prothrombin time), renal function tests, liver enzymes, C-reactive protein (CRP), and procalcitonin if clinically indicated.
• Obtain at least two sets of peripheral blood cultures; if a central venous catheter is present, obtain additional cultures from each lumen.
• Urinalysis (including microscopy) and urine culture when urinary tract infection is clinically suspected
• Sputum Gram stain and culture in patients with respiratory symptoms
• Stool culture in patients with diarrhea
• Chest radiography in patients with respiratory symptoms or clinical suspicion of pneumonia

Additional diagnostic evaluation in the absence of improvement or with clinical deterioration:

• Imaging with CT of the chest and abdomen based on the clinical presentation.
• Bronchoalveolar lavage when pulmonary infection is suspected and the diagnosis remains unclear
• Echocardiography when endocarditis is suspected or when a cardiac etiology is considered
• Funduscopic examination when ocular symptoms are present or disseminated fungal infection is suspected
• Additional serologic testing and imaging based on the clinical presentation

Prophylaxis of Febrile Neutropenia

Prophylactic use of G-CSF (granulocyte colony-stimulating factor) is appropriate for chemotherapy regimens associated with a ≥20% risk of febrile neutropenia (e.g., MVAC, paclitaxel/carboplatin, or PEI). For regimens with an intermediate risk of 10–20%, primary prophylaxis can be appropriate when additional risk factors are present (e.g., older age, clinically relevant comorbidities, prior febrile neutropenia, or extensive pretreatment). G-CSF is used as secondary prophylaxis when neutropenia delays potentially curative chemotherapy or necessitates dose reductions (e.g., BEP for germ cell tumors). Example dosing: pegfilgrastim 6 mg subcutaneously once per cycle, administered no earlier than 24 hours after completion of chemotherapy.

Treatment of Asymptomatic Neutropenia

Therapeutic G-CSF for asymptomatic neutropenia is not recommended. Hygienic precautions and close monitoring of body temperature remain important [Table Reverse Isolation]. Antibacterial, antifungal, or antiviral prophylaxis should not be routine for all patients; clinicians should individualize it based on the clinical context, expected depth and duration of neutropenia, and patient-specific risk factors.

Treatment of Febrile Neutropenia

Febrile neutropenia is an oncologic emergency. Clinicians should obtain blood cultures and start empiric antibiotic therapy as soon as possible, ideally within 60 minutes of presentation. The empiric regimen should reflect the patient’s risk profile (e.g., MASCC), clinical stability, suspected source of infection, and local resistance patterns. Hygienic precautions remain important [Table Reverse Isolation].

Low-risk patients (clinically stable, able to reliably take oral medications, without clinically significant comorbidities, and with dependable follow-up) can often receive outpatient oral antibiotic therapy, typically ciprofloxacin plus amoxicillin/clavulanate. Avoid an oral fluoroquinolone-based regimen when the patient has already received fluoroquinolone prophylaxis or when local fluoroquinolone resistance rates are high.

High-risk patients require broad intravenous empiric therapy, typically with piperacillin/tazobactam, cefepime, or a carbapenem (imipenem or meropenem).

If the patient does not improve clinically or fever persists despite appropriate antibiotic therapy, pursue additional evaluation (see above) and adjust therapy as needed, including broadening antibacterial coverage or initiating antifungal therapy when clinically indicated.

Indications for G-CSF in Febrile Neutropenia

Therapeutic use of G-CSF in febrile neutropenia is appropriate only in patients with risk factors for a complicated course:

• Expected duration of neutropenia >10 days
• ANC <100/μl
• Sepsis, hypotension, or pneumonia
• Prior invasive fungal infections
• Age >60 years
• Poor performance status
• High tumor burden
• Significant comorbidity (e.g., diabetes, COPD, or hepatic, renal, or cardiac failure)

Dosing of G-CSF

For example, administer filgrastim 5 μg/kg subcutaneously once daily, starting 24–72 hours after completion of chemotherapy. Discontinue therapy after clinical recovery and neutrophil recovery, for example when the ANC is >1000–1500/μl on two consecutive days.

References

J. Klastersky et al., “Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.,” Annals Oncol, vol. 27, no. suppl 5, pp. v111–v118, 2016, doi: 10.1093/annonc/mdw325.

Retz, M. & Gschwend, J. (ed.) Medikamentöse Tumortherapie in der Uroonkologie
Springer Verlag Berlin Heidelberg, 2010.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie

  Deutsche Version: Prophylaxe und Therapie der chemotherapie-induzierten Neutropenie

Urology-Textbook.com – Choose the Ad-Free, Professional Resource

This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.

New release: The first edition of the Urology Textbook as an e-book—ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.